Financial Performance Overview (Consolidated)

Dr Lal PathLabs Limited reported strong financial results for Q1 FY27 (quarter ended June 30, 2026) with significant growth across key metrics:

Revenue Performance:

  • Revenue increased by 19.1% to Rs 798 crore in Q1 FY27 from Rs 670 crore in Q1 FY26

Profitability Metrics:

  • EBITDA increased by 28.7% to Rs 247 crore from Rs 192 crore YoY
  • EBITDA margin expanded to 31.0% from 28.7% YoY
  • PAT increased by 27.2% to Rs 170 crore from Rs 134 crore YoY
  • PAT margin improved to 21.4% from 20.0% YoY
  • EPS increased by 27.8% to Rs 10.1 from Rs 7.9 YoY
  • PBT increased by 26.3% to Rs 229 crore from Rs 181 crore YoY
  • PBT margin improved to 28.7% from 27.0% YoY

Expense Breakdown:

  • Material consumed: Rs 152 crore (vs Rs 129 crore in Q1 FY26)
  • Employee benefit expenses: Rs 133 crore (vs Rs 124 crore in Q1 FY26)
  • Fees to collection centres: Rs 116 crore (vs Rs 96 crore in Q1 FY26)
  • Other expenses: Rs 150 crore (vs Rs 129 crore in Q1 FY26)
  • Depreciation cost: Rs 44 crore (vs Rs 35 crore in Q1 FY26)
  • Finance cost: Rs 6 crore (vs Rs 5 crore in Q1 FY26)
  • Income tax: Rs 58 crore (vs Rs 47 crore in Q1 FY26)

Other Financial Items:

  • Other income: Rs 32 crore (vs Rs 28 crore in Q1 FY26)
  • Cash and cash equivalents as of June 30, 2026: Rs 1,693 crore

Dividend Declaration

  • Interim dividend of 50% declared, amounting to Rs 5 per share

Strategic Acquisitions

The company announced two strategic acquisitions:

1. Sunshine Healthcare Limited, Ghana Acquisition:

  • Acquired 80% equity stake in Sunshine Healthcare Limited, Ghana
  • Company is engaged in diagnostic business
  • Consideration not exceeding GHS 45.6 million

2. Neuome Technologies Private Limited Investment:

  • Acquired 30% equity stake in Neuome Technologies Private Limited
  • Company is engaged in innovative solutions in sample preservation and biobanking
  • Consideration not exceeding Rs 3.5 crore

Operational Overview

As of March 31, 2026, the company's operational footprint includes:

  • 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Labs at Kolkata, Bangalore & Mumbai)
  • 7,727 Patient Service Centers (PSCs)
  • 13,935 Pick-up Points (PUPs)

The company serves individual patients, hospitals, healthcare providers, and corporate customers through its integrated nationwide network.

Management Contacts

  • Ved Goel: Group Chief Financial Officer & CEO- International Business
  • Vinay Gujral: Company Secretary & Compliance Officer
  • Kritika Khatwani: Adfactors PR contact